Differences in pharmacological activities of the antioxidant flavonoid MonoHER in humans and mice are caused by variations in its metabolic profile

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 6, 2011, Pages 852-859

  Jacobs, H ^a   Koek, G H ^a   Peters, R ^b   Moalin, M ^a   Tack, J ^c   Van Der Vijgh, W J ^a   Bast, A ^a   Haenen, G R ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DSM RESOLVE   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

7 MONO O (BETA HYDROXYETHYL)RUTOSIDE; ANTIOXIDANT; FLAVONOID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILIARY EXCRETION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; METHYLATION; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REACTION ANALYSIS; SPECIES DIFFERENCE;

ADULT; ANIMALS; ANTIOXIDANTS; BILE; CHROMATOGRAPHY, LIQUID; FEMALE; GLUCURONIDES; HUMANS; HYDROXYETHYLRUTOSIDE; INFUSIONS, INTRAVENOUS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; METHYLATION; MICE; SPECIES SPECIFICITY;

EID: 81355139607     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.200     Document Type: Article

References (43)

1. Bast, A., Haenen, G.R., Bruynzeel, A.M. & Van der Vijgh, W.J. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials. Cardiovasc. Toxicol. 7, 154-159 (2007). (Pubitemid 47339864)
2. Lipshultz, S.E. et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J. Clin. Oncol. 23, 2629-2636 (2005). (Pubitemid 46179451)
3. Singal, P.K. & Iliskovic, N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339, 900-905 (1998). (Pubitemid 28446849)
4. Horenstein, M.S., Vander Heide, R.S. & L'Ecuyer, T.J. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol. Genet. Metab. 71, 436-444 (2000).
5. Xu, M.F., Tang, P.L., Qian, Z.M. & Ashraf, M. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci. 68, 889-901 (2001). (Pubitemid 32168065)
6. Doroshow, J.H., Locker, G.Y. & Myers, C.E. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J. Clin. Invest. 65, 128-135 (1980). (Pubitemid 10214339)
7. Iarussi, D., Indolfi, P., Galderisi, M. & Bossone, E. Cardiac toxicity after anthracycline chemotherapy in childhood. Herz 25, 676-688 (2000).
8. Julicher, R.H., Sterrenberg, L., Haenen, G.R., Bast, A. & Noordhoek, J. The effect of chronic adriamycin treatment on heart kidney and liver tissue of male and female rat. Arch. Toxicol. 61, 275-281 (1988). (Pubitemid 18058436)
9. Amic, D., Davidovic-Amic, D., Beslo, D., Rastija, V., Lucic, B. & Trinajstic, N. SAR and QSAR of the antioxidant activity of flavonoids. Curr. Med. Chem. 14, 827-845 (2007). (Pubitemid 46477715)
10. Rice-Evans, C.A., Miller, N.J. & Paganga, G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic. Biol. Med. 20, 933-956 (1996). (Pubitemid 26157509)
11. van Acker, S.A., Tromp, M.N., Haenen, G.R., van der Vijgh, W.J. & Bast, A. Flavonoids as scavengers of nitric oxide radical. Biochem. Biophys. Res. Commun. 214, 755-759 (1995).
12. van Acker, S.A. et al. Structural aspects of antioxidant activity of flavonoids. Free Radic. Biol. Med. 20, 331-342 (1996). (Pubitemid 26077855)
13. Haenen, G.R., Jansen, F.P. & Bast, A. The antioxidant properties of five O-(-b-hydroxyethyl)-rutosides of the flavonoid mixture Venoruton. Phlebology (suppl.1), 10-7 (1993). (Pubitemid 24064735)
14. van Acker, F.A., van Acker, S.A., Kramer, K., Haenen, G.R., Bast, A. & van der Vijgh, W.J. 7-monohydroxyethylrutoside protects against chronic doxorubicininduced cardiotoxicity when administered only once per week. Clin. Cancer Res. 6, 1337-1341 (2000). (Pubitemid 30226217)
15. van Acker, S.A. et al. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin. Cancer Res. 3, 1747-1754 (1997). (Pubitemid 27444713)
16. Jacobs, H., Peters, R., den Hartog, G.J., van der Vijgh, W.J., Bast, A. & Haenen, G.R. Identification of the metabolites of the antioxidant flavonoid 7-mono-O-({beta}-hydroxyethyl)-rutoside in mice. Drug Metab. Dispos.39, 750-756 (2011).
17. Bruynzeel, A.M. et al. The effect of monohydroxyethylrutoside on doxorubicininduced cardiotoxicity in patients treated for metastatic cancer in a phase II study. Br. J. Cancer 97, 1084-1089 (2007). (Pubitemid 47587012)
18. Abou El Hassan, M.A.et al. Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice. Cancer Chemother. Pharmacol 52, 371-376 (2003). (Pubitemid 37363609)
19. Willems, A.M., Bruynzeel, A.M., Kedde, M.A., van Groeningen, C.J., Bast, A. & van der Vijgh, W.J. A phase I study of monohydroxyethylrutoside in healthy volunteers. Cancer Chemother. Pharmacol. 57, 678-684 (2006).
20. Koster, H., Halsema, I., Scholtens, E., Knippers, M. & Mulder, G.J. Dose-dependent shifts in the sulfation and glucuronidation of phenolic compounds in the rat in vivo and in isolated hepatocytes. The role of saturation of phenolsulfotransferase. Biochem. Pharmacol. 30, 2569-2575 (1981). (Pubitemid 11042505)
21. Baba, S. et al. Bioavailability of (-)-epicatechin upon intake of chocolate and cocoa in human volunteers. Free Radic. Res. 33, 635-641 (2000). (Pubitemid 32103703)
22. Doerge, D.R., Chang, H.C., Churchwell, M.I. & Holder, C.L. Analysis of soy isoflavone conjugation in vitro and in human blood using liquid chromatography-mass spectrometry. Drug Metab. Dispos. 28, 298-307 (2000). (Pubitemid 30137054)
23. Lee, M.J. et al. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol. Biomarkers Prev. 11, 1025-1032 (2002).
24. Manach, C., Morand, C., Gil-Izquierdo, A., Bouteloup-Demange, C. & Ry, C. Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. Eur. J. Clin. Nutr. 57, 235-242 (2003). (Pubitemid 36240474)
25. Setchell, K.D. et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J. Nutr. 131, 1362S-1375S (2001). (Pubitemid 32268489)
26. Shelnutt, S.R., Cimino, C.O., Wiggins, P.A., Ronis, M.J. & Badger, T.M. Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. Am. J. Clin. Nutr. 76, 588-594 (2002). (Pubitemid 34920836)
27. Zhang, Y., Hendrich, S. & Murphy, P.A. Glucuronides are the main isoflavone metabolites in women. J. Nutr. 133, 399-404 (2003). (Pubitemid 36172890)
28. Radominska-Pandya, A., Czernik, P.J., Little, J.M., Battaglia, E. & Mackenzie, P.I. Structural and functional studies of UDP- glucuronosyltransferases. Drug Metab. Rev. 31, 817-899 (1999).
29. Miners, J.O. & Mackenzie, P.I. Drug glucuronidation in humans. Pharmacol. Ther. 51, 347-369 (1991).
30. Jacobs, H. et al. Characterization of the glutathione conjugate of the semisynthetic flavonoid monoHER. Free Radic. Biol. Med. 46, 1567-1573 (2009).
31. Jacobs, H., Moalin, M., Bast, A., van der Vijgh, W.J. & Haenen, G.R. An essential difference between the flavonoids monoHER and quercetin in their interplay with the endogenous antioxidant network. PLoS ONE 5, e13880 (2010).
32. Zhu, B.T. Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr. Drug Metab. 3, 321-349 (2002). (Pubitemid 34625043)
33. Spencer, J.P., Abd-el-Mohsen, M.M. & Rice-Evans, C. Cellular uptake and metabolism of flavonoids and their metabolites: implications for their bioactivity. Arch. Biochem. Biophys. 423, 148-161 (2004). (Pubitemid 38198224)
34. Spencer, J.P., Kuhnle, G.G., Williams, R.J. & Rice-Evans, C. Intracellular metabolism and bioactivity of quercetin and its in vivo metabolites. Biochem. J. 372, 173-181 (2003). (Pubitemid 36609619)
35. Walle, T. Methylation of dietary flavones increases their metabolic stability and chemopreventive effects. Int. J. Mol. Sci. 10, 5002-5019 (2009).
36. Spencer, J.P., Schroeter, H., Rechner, A.R. & Rice-Evans, C. Bioavailability of flavan-3-ols and procyanidins: gastrointestinal tract influences and their relevance to bioactive forms in vivo. Antioxid. Redox Signal. 3, 1023-1039 (2001). (Pubitemid 34027360)
37. Passamonti, S. et al. Bioavailability of flavonoids: a review of their membrane transport and the function of bilitranslocase in animal and plant organisms. Curr. Drug Metab. 10, 369-394 (2009).
38. Strobel, P., Allard, C., Perez-Acle, T., Calderon, R., Aldunate, R. & Leighton, F. Myricetin, quercetin and catechin-gallate inhibit glucose uptake in isolated rat adipocytes. Biochem. J. 386, 471-478 (2005). (Pubitemid 40445871)
39. Huang, S. & Czech, M.P. The GLUT4 glucose transporter. Cell Metab. 5, 237-252 (2007). (Pubitemid 46477860)
40. Jacobs, H., Bast, A., Peters, G.J., van der Vijgh, W.J. & Haenen, G.R. The semisynthetic flavonoid monoHER sensitises human soft tissue sarcoma cells to doxorubicin-induced apoptosis via inhibition of nuclear factor-kappaB. Br. J. Cancer 104, 437-440 (2011).
41. Abou El Hassan, M.A., Touw, D.J., Wilhelm, A.J., Bast, A. & van der Vijgh, W.J. Stability of monoHER in an aqueous formulation for i.v. administration. Int. J. Pharm. 211, 51-56 (2000). (Pubitemid 32008383)
42. Koek, G.H. et al. Oesophageal clearance of acid and bile: a combined radionuclide, pH, and Bilitec study. Gut 53, 21-26 (2004). (Pubitemid 38083005)
43. Bartholom, R. et al. Deconjugation kinetics of glucuronidated phase II flavonoid metabolites by beta-glucuronidase from neutrophils. Drug Metab. Pharmacokinet. 25, 379-387 (2010).